Table 3.

Prevalence of the TMPRSS2:ERG gene fusion in men with prostate cancer from studies in the meta-analysis

	Overall fusion analysis		Fusion mechanism analysis
Characteristic	Sample size	Prevalence fusion positive	Sample size	Prevalence fusion-by-deletion^a
Overall	10,779	46.9%	1,390	63.7%
Assay^b
FISH	3,146	42.4%	1,008	62.6%
RT-PCR	1,311	52.2%	NA	NA
IHC	4,763	51.8%	NA	NA
Cohort continent^b,^c
Asia	837	23.4%	67	61.2%
Europe	4,926	53.6%	380	63.9%
North America	3,217	47.6%	530	63.2%
Tissue assayed
Biopsy	611	43.0%	190	60.0%
Lymph node	71	59.2%	0	NA
RP specimen	9,220	48.6%	1,035	63.1%
TURP specimen	803	29.8%	165	71.5%
Urine	74	36.5%	0	NA

Abbreviations: RP, radical prostatectomy.

↵^aAmong those for whom fusion mechanism was determined.
↵^bIn radical prostatectomy specimens only.
↵^cExcludes cohorts with patients from multiple regions or areas outside those listed.